Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5881-5888
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881
Table 2 Correlation of KRAS gene status and phosphatase and tensin protein expression with clinical response to cetuximab in previously treated colorectal cancer patients n (%)
| KRAS | PTEN | |||||
| Mutation | No mutation | P | Positive | Negative | P | |
| CR | 0 (0) | 2 (5.1) | 0.001 | 2 (5.4) | 0 (0) | 0.001 |
| PR | 1 (4.5) | 16 (41.0) | 16 (43.2) | 1 (4.2) | ||
| SD | 7 (31.8) | 17 (43.6) | 10 (27.0) | 14 (58.3) | ||
| PD | 14 (63.6) | 4 (10.3) | 9 (24.3) | 9 (37.5) | ||
| Total | 22 (100) | 39 (100) | 37 (100) | 24 (100) | ||
-
Citation: Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of
KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16(46): 5881-5888 - URL: https://www.wjgnet.com/1007-9327/full/v16/i46/5881.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i46.5881